tolvaptan has been researched along with hydrochlorothiazide in 6 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (hydrochlorothiazide) | Trials (hydrochlorothiazide) | Recent Studies (post-2010) (hydrochlorothiazide) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 6,921 | 2,165 | 1,262 |
| Protein | Taxonomy | tolvaptan (IC50) | hydrochlorothiazide (IC50) |
|---|---|---|---|
| Carbonic anhydrase 2 | Homo sapiens (human) | 5.4954 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bramer, SL; Bricmont, P; Shoaf, SE; Zimmer, CA | 1 |
| Mager, DE; Mallikaarjun, S; Shoaf, SE; Van Wart, SA | 1 |
| Hirose, T; Ito, S; Kinugasa, S; Mori, T; Muroya, Y; Oba-Yabana, I; Ohsaki, Y; Sato, E; Takahashi, C; Wang, A | 1 |
| Fenton, RA; Gansevoort, RT; Geurts, F; Hoorn, EJ; Kramers, BJ; Meijer, E; Salih, M; Xue, L; Zietse, R | 1 |
1 review(s) available for tolvaptan and hydrochlorothiazide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for tolvaptan and hydrochlorothiazide
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cross-Over Studies; Diuretics; Drug Interactions; Furosemide; Humans; Hydrochlorothiazide; Male; Osmolar Concentration; Renin; Sodium; Tolvaptan | 2007 |
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
Topics: Adult; Antihypertensive Agents; Benzazepines; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Models, Biological; Renal Insufficiency; Tolvaptan; Young Adult | 2013 |
3 other study(ies) available for tolvaptan and hydrochlorothiazide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Diuretics; Drug Therapy, Combination; Gene Expression; Glomerular Filtration Rate; Hydrochlorothiazide; Male; Nitric Oxide Synthase Type I; Polycystic Kidney Diseases; Polyuria; Prostaglandin-E Synthases; Rats; Renin; RNA, Messenger; Tolvaptan; Urine | 2019 |
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Dinoprostone; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Kidney; Male; Osmoregulation; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency; Tolvaptan | 2023 |